An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Ingrezza

Chemical Namevalbenazine
Dosage FormCapsule (oral; 40 mg, 80 mg)
Drug ClassInhibitors
SystemMusculoskeletal
CompanyNeurocrine Biosciences, Inc.
Approval Year2017

Indication

  • To treat tardive dyskinesia in adults.
Last updated on 11/11/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ingrezza (Valbenazine) Prescribing Information 2017Neurocrine Biosciences, Inc., San Diego, CA
Document TitleYearSource
A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. 2019Therapeutic Advances in Psychopharmacology
Treatment of tardive dyskinesia with VMAT-2 inhibitors: A systematic review and meta-analysis of randomized controlled trials. 2018Drug Design, Development and Therapy
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: A systematic review. 2018Journal of Comparative Effectiveness Research